Enzymatic mechanisms of resistance to aminoglycoside antibiotics were first reported in 1967 by UMEZAWA and his colleagues. 1,2) They demonstrated all the three types of aminoglycoside-modifying enzymes in clinicallyisolated resistant bacteria carrying R plasmids; i. e., an aminoglycoside acetyltransferase, AAC(6')3) as well as a phosphotransferase, APH(3'),4) that inactivated kanamycin (KM), and an adenylyltransferase, AAD(3"),5) that inactivated streptomycin (SM). On the basis of these findings, they predicted structures refractory to these enzymes and eventually synthesized dibekacin (DKB) as the first rationally designed semisynthetic aminoglycoside.6) Subsequently, arbekacin (ABK)7) having the 1-N-[(S)-4-amino- 2-hydroxybutyryl] side chain were synthesized as in the case of amikacin (AMK).8) Among a lot of aminoglycoside derivatives synthesized for active agents against resistant bacteria, only ABK showed an excellent activity against all of methicillin-resistant Staphylococcus aureus (MRSA) strains containing any sort of aminoglycoside-modifying enzyme available in the 1980s. Therefore, ABK was approved as a chemotherapeutic agent for the treatment of infections caused extensively until today. Only a small number of MRSA ABK-resistance due to a bifunctional enzyme APH(2")/ AAC(6') have emerged12,13) so that the incidence of ABK-registant MRSA strains has been very low. However, one cannot rule out the possibility of emergence in the future of novel ABK-resistant strains, since ABK contains several amino and hydroxyl groups that may be modified by enzymes such as AAC(3), AAC(2') and AAC(6').
To check these possibility, we attempted to use AACs available from actinomycetes such as aminoglycosideproducers. First, we exposed ABK to AAC (2') derived from a kasugamycin-producing strain, Streptomyces kasugaensis MB273. Consequently it turned out that ABK was readily converted to the 2'-N-acetyl derivative retaining antibiotic activity, indicating that AAC (2')-dependent aminoglycoside resistant bacteria could not be resistant to ABK.14) While, an inactivated product, 3-N-acetyl KM was isolated by the enzymatic reaction of KM with an AAC (3) obtained from S. griseus SS-1198PR, a KM-resistant mutant derived from a wild type SM-producing strain (S. griseus SS-1198). Although this enzyme was first designated AAC (3)-V,15) it was renamed AAC(3)-X as a new aminoglycoside-modifying en-
In the present study, ABK, AMK and DKB were exposed to AAC (3)-X of S. griseus origin. Interestingly, ABK and AMK that have the same 1-N-aryl side chain turned out to be modified by acetylation at the 3"-amino group that has never been reported in any aminoglycoside, whereas DKB lacking the side chain was converted to 3-N-acetyl DKB by the intrinsic action of AAC (3)-X ( Fig. 1) . In this paper, the formation, isolation, structural elucidation and antimicrobial activity of enzymatic reaction products of ABK, AMK and DKB by AAC (3)-X are presented.
Results
In a preliminary study on acetylation with a cell free The acetylated product in the enzymatic reaction mixture of ABK and a cell free extract of S. lividans TK21/pANT3-1 was isolated by column chromatography on Amberlite CG-50 (NH+4) resin in a good yield. FAB-MS of the product provided m/z 595 (M+H)+ indicating monoacetylated ABK. As shown in Tables 1   and 2 , the 1H and 13C NMR spectra of the acetylated product were compared with those of ABK in an acidic D2O. The 1H NMR spectrum of the product showed an Bold letters show lower-field shifts due to the N-acetylation.
68.3, respectively). Thus, the structure of the product was elucidated to be 3"-N-acetyl ABK. The enzymatic reaction of AMK by 48-hour incubation gave 3"-N-acetyl AMK in 35% yield. However, the product of DKB was the 3-N-acetyl derivative similar to that of KM.15)
As shown in Table 3 , by the enzymatic reaction with the enzyme AAC(3)-X, ABK and AMK that have the same 1-N-acyl side chain, (S)-4-amino-2-hydroxybutyric acid, were converted into 3"-N-acetyl ABK and 3"-Nacetyl AMK, respectively, instead of 3-N-acetyl products. As expected, the modification product of DKB was confirmed to be 3-N-acetyl DKB. On the other hand, two known enzymes, AAC (3)-III produced by Pseudomonas aeruginosa PST117) and AAC (3)-IV produced by Escherichia coli JR225,18) were not able to acetylate ABK and AMK, but readily converted KM and DKB to the 3-N-acetyl derivatives.
Furthermore, a new product, 3"-N-acetyl ABK showed a substantial antibiotic activity (55% activity of ABK against Bacillus subtilis PCI219) as same as 2'-N-acetyl ABK (42% activity of ABK).15) Minimum inhibitory concentrations of 3"-N-acetyl ABK are shown in Table 4 .
Discussion
It was surprise to us to learn that AAC (3)-X was capable of converting both ABK and AMK to novel THE JOURNAL OF ANTIBIOTICS AUG. 1998 Table 2 . 13C NMR spectral data. that AACs derived from P, aeruginosa and E, coli failed to do the 3"-N-acetylation, although these enzymes produced 3-N-acetyl derivatives from KM and DKB. This means that AAC (3)-X has a unique catalytic property.
The other point to note is that 3"-N-acetyl ABK showed a substantial antibiotic activity whereas no significant activity was observed with 3"-N-acetyl AMK in spite of their structural similarity. However, there is no doubt that the antibiotic activity of the monoacetyl derivatives is the advantage for ABK to keep itself refractory to the emergence of resistant bacteria depending on AAC (3) and AAC (2'). AAC (3) Producing Strains S. lividans TK21/pANT3-1 transformed with a KMresistant plasmid, pANT3-1 containing a KM resistance (AAC(3)-X) gene derived from S. griseus SS-1198PR15) was used as the AAC(3)-X producer. The AAC(3)-X gene was discovered through the protoplast regeneration of the wild type strain, S. griseus SS-1198 and cloned into pIJ702 to produce pANT3-1. S. lividans TK21/ pANT3-1 is highly resistant to KM and DKB (>400 (Table 3) . AAC (3)-III producing strain, P. aeruginosa PST117) and AAC (3)-IV producing E. coli JR22518) were kindly provided by Professor J. DAVIES.
Cell Free Extracts
A cell free extract (S-30) of S. lividans TK21/pANT3-1 was prepared by the method described in a previous paper.15) Cells of P, aeruginosa PST1 and E. coli JR225 were disrupted sonically and then centrifuged at Isolation of 3"-N-Acetylarbekacin (3"AcABK)
The enzymatic reaction was carried out in a mixture 15ml, 50mM acetyl CoA (Na salt, Sigma) 2ml, the cell free extract of S. lividans TK21/pANT3-1 (69.6mg protein/ml) 1ml and 1M phosphate buffer (pH 7.0) 2ml a column of Amberlite CG-50 (NH+4, 20ml). After being washed with H2O (40ml) followed by 0.4% aqueous ammonia (100ml), the column was eluted with 1% aqueous ammonia (100ml). Approximately 2-ml fractions of the eluate were collected, and both ninhydrinpositive and Rydon-Smith-positive products in the fractions were detected by HYPE and TLC. Fractions Tables 1 and 2 . The antibacterial activity against B. subtilis PCI219 by an ordinary cup method showed 55% activity of ABK. The MICs are shown in Table 3 .
Isolation of 3"-N-Acetylamikacin (3"AcAMK) 50mM acetyl CoA 1.0ml, the cell free extract of S. lividans TK21/pANT3-1 (69.6mg protein/ml) 1.0ml and 1M
phosphate buffer (pH 7.0) 1.0ml was passed through a column of Amberlite CG-50 (NH+4, 20ml). After being washed with H2O (40ml) and 0.4% aqueous ammonia (100ml), the column was eluted with 1.5% aqueous ammonia. Approximately 2-ml fractions of the eluate were collected, and both ninhydrin-positive and RydonSmith-positive products in the fractions were detected by concentrated to obtain pure 3"AcAMK 
